

RECEIVED

APR 23 2003

Docket No.: C17858/120103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APR 21 PM 1:15
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
APR 21 PM 1:15
2003
#7A
1600/2900

In re Application of:

STEVEN J. RYCHNOVSKY

Serial No.: 09/871,441

Examiner: R. Henley, III

Filed: May 31, 2001

Art Unit: 1614

For: METHOD FOR IMPROVING
TREATMENT SELECTIVITY AND
EFFICACY USING INTRAVASCULAR
PHOTODYNAMIC THERAPY

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

In the Specification

A. Replace the paragraph at page 4, line 20 through page 5, line 8
with the following paragraph:

Other studies have investigated the inhibition of neointima formation in natural vein grafts in which, prior to implantation, the graft receives a PDT treatment using 675 nm light (G. M. LaMuraglia, et al., Photodynamic Therapy of Vein Grafts: Suppression of Intimal Hyperplasia of the Vein Graft but not the Anastomosis, J Vascular Surg, 21, 1995). Still further studies have investigated the reduction or stabilization of plaques in diseased artery animal models using a photosensitizer delivered systemically and excited with either external or intravascular light with a wavelength near 730 nm. These studies led to the application of PDT in human clinical trials using Lutetium texaphyrin (LuTex) in combination with a laser source having a wavelength near 730 nm (S. G. Rockson, et al., Photoangioplasty: An Emerging Clinical Cardiovascular Role for Photodynamic Therapy, Circulation, 102, 591-96, 2000). These human clinical trials have two primary efficacy endpoints: inhibition of restenosis

A